Heparin and ACS

Dr. Josh Farkas critically examines the entrenched practice of administering heparin in the noninvasive management of non-ST elevation myocardial infarction (NSTEMI). He highlights that, although heparin may transiently reduce the incidence of reinfarction during administration, this benefit is not sustained after discontinuation due to a rebound in infarction rates. This pattern suggests that short-term heparin therapy merely delays reinfarction without providing lasting advantages. Farkas points out that many clinical trials supporting heparin's use fail to monitor patients beyond the anticoagulation period, leading to misleading conclusions about its efficacy. He also notes that the AHA/ACC guidelines continue to recommend heparin for NSTEMI management, despite acknowledging that supporting studies were conducted in an era preceding dual antiplatelet therapy and early revascularization. This discrepancy raises questions about the current relevance of routine heparin use in NSTEMI patients managed noninvasively.

In his comprehensive review, Justin Morgenstern critically examines the routine use of heparin in ACS, particularly focusing on unstable angina and NSTEMI He highlights that, despite heparin's widespread adoption, the evidence supporting its efficacy is not robust. Key randomized controlled trials (RCTs) have demonstrated that while heparin may reduce the incidence of myocardial infarction (MI) during the initial treatment phase, this benefit does not persist beyond the first week. Moreover, heparin administration is associated with a significant increase in major bleeding events, with approximately 1 in 33 patients experiencing severe bleeding complications. Morgenstern concludes that, given the lack of sustained benefit and the heightened risk of harm, the routine use of heparin in NSTEMI and unstable angina should be reconsidered. He advocates for a more individualized approach, weighing the potential risks and benefits before initiating heparin therapy in these patients.

The First10EM review critically examines the widespread routine use of heparin in STEMI and PCI, emphasizing that its efficacy has never been proven in high-quality randomized controlled trials. While heparin is standard practice in PCI and recommended in guidelines, these recommendations are largely based on historical precedent and expert consensus rather than strong evidence. The available studies suggest that while heparin reduces thrombotic complications during PCI, this benefit may be offset by an increased risk of major bleeding. Additionally, modern management strategies, including dual antiplatelet therapy (DAPT) and rapid reperfusion, may already provide sufficient therapy, making the incremental benefit of heparin unclear. Given this lack of direct evidence supporting heparin’s use in PCI, the review suggests that reassessing its necessity in certain STEMI patients could be warranted, particularly in those at higher bleeding risk.

A retrospective cohort study of 6,804 NSTEMI patients undergoing PCI found no mortality benefit from pre-procedural parenteral anticoagulation but a significant increase in major bleeding (2.5% vs. 1.0%, aOR 1.94, p = 0.004). Long-term follow-up (median 2.96 years) confirmed no survival advantage, while bleeding risk remained elevated, particularly in the first 30 days (aHR 1.43, p = 0.04). These findings suggest that routine anticoagulation in NSTEMI patients may not be necessary and could cause more harm than benefit, particularly in the era of DAPT and early PCI.